Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Diagnostic evaluation of dysphagia in multiple sclerosis patients using a Persian version of DYMUS questionnaire.

Authors:
Sahar Danesh Pajouh Negin Moradi Mohammad Jafar Shaterzadeh Yazdi Seyed Mahmoud Latifi Mohammad Mehravar Nastaran Majdinasab Ali Reza Olapour Majid Soltani Fatemeh Khanchezar

Mult Scler Relat Disord 2017 Oct 1;17:240-243. Epub 2017 Sep 1.

Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background: Multiple sclerosis is a chronic neurological disease that may cause swallowing disorders. Dysphagia is a common problem, which patients with different levels of disability may encounter, but it is usually underestimated; therefore, effective assessments need to be performed before any serious complications. The aim of this study was to identify the frequency and characteristics of dysphagia in multiple sclerosis patients of Khuzestan MS society, using a Persian version of Dysphagia in Multiple Sclerosis (DYMUS) questionnaire.

Method: 105 consecutive MS patients (84 F and 21 M, mean age 33.8 ± 8.5 years, mean disease duration 3.5 ± 3.1 years, mean Expanded Disability Status Scale (EDSS) 1.8 ± 1.3) participated in the study and the DYMUS questionnaire was administered by a trained speech therapist.

Results: The results have shown that 55 MS patients (52.4%) had dysphagia and the dysphagia was significantly associated with the disease course of MS (p = 0.02). However, significant associations between DYMUS values and EDSS, disease duration, age, and gender were not observed. (Respectively, p = 0.4, p = 0.09, p = 0.1, p = 1.0). In the dysphagia group, based on dysphagia severity, 17.1% and 35.2% of patients had mild and alarming dysphagia, respectively. Although, the patients with alarming dysphagia had longer disease duration, higher EDSS score and more with SP, PP and PR disease course than the patients with mild dysphagia, these differences were not significant.

Conclusion: The oropharyngeal dysphagia in MS patients is very common even in early stages of the disease; therefore, it is important to assess these patients carefully and to initiate a treatment program if needed.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.msard.2017.08.012DOI Listing
October 2017

Publication Analysis

Top Keywords

multiple sclerosis
16
dysphagia multiple
12
disease duration
12
dysphagia
12
patients
10
patients mild
8
alarming dysphagia
8
disease course
8
dysphagia patients
8
dymus questionnaire
8
persian version
8
sclerosis patients
8
disease
7
associated disease
4
gender observed
4
dysphagia dysphagia
4
524% dysphagia
4
age gender
4
dysphagia associated
4
course 002
4

Altmetric Statistics


Show full details
4 Total Shares
4 Tweets
4 Citations

Similar Publications

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.

Authors:
Ho Jin Kim Ichiro Nakashima Shanthi Viswanathan Kai-Chen Wang Shulian Shang Larisa Miller Marcus Yountz Dean M Wingerchuk Sean J Pittock Michael Levy Achim Berthele Natalia Totolyan Jacqueline Palace Michael H Barnett Kazuo Fujihara

Mult Scler Relat Disord 2021 Feb 20;50:102849. Epub 2021 Feb 20.

Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aobaku, Sendai, Miyagi 980-8574, Japan; Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, 1 Hikariga-oka, Fukushima City, Fukushima 960-1295, Japan; Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, 7-115, Yatsuyamada, Koriyama, Fukushima 963-8563, Japan. Electronic address:

Background Eculizumab, a terminal complement inhibitor, significantly reduced the risk of relapse compared with placebo in patients with anti-aquaporin-4 immunoglobulin G-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the PREVENT trial. We report efficacy and safety analyses in Asian patients in PREVENT and its open-label extension (OLE). Methods PREVENT was a double-blind, randomized, phase 3 trial. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Whole Brain Adiabatic T and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings.

Authors:
Ivan Jambor Aida Steiner Marko Pesola Timo Liimatainen Marcus Sucksdorff Eero Rissanen Laura Airas Hannu J Aronen Harri Merisaari

J Magn Reson Imaging 2021 Mar 6. Epub 2021 Mar 6.

Department of Diagnostic Radiology, University of Turku, Turku, Finland.

Background: In preclinical models of multiple sclerosis (MS), both adiabatic T (T ) and relaxation along a fictitious field (RAFF) imaging have demonstrated potential to noninvasively characterize MS.

Purpose: To evaluate the feasibility of whole brain T and RAFF imaging in healthy volunteers and patients with MS.

Study Type: Single institutional clinical trial. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.

Authors:
Kristen M Krysko Antje Bischof Bardia Nourbakhsh Roland G Henry Nisha Revirajan Michael Manguinao Khang Nguyen Amit Akula Yan Li Emmanuelle Waubant

Ann Clin Transl Neurol 2021 Mar 6. Epub 2021 Mar 6.

UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA.

Objective: To assess feasibility, tolerability, and safety of N-acetyl cysteine (NAC) for fatigue in progressive MS. Secondary objectives evaluated changes in fatigue and oxidative pathway biomarkers on NAC versus placebo.

Methods: Individuals with progressive MS with Modified Fatigue Impact Scale (MFIS) > t38 were randomized 2:1 to NAC 1250mg TID or placebo for 4 weeks. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Functional genomic analyses highlight a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells and underlying myelin dysregulation in the aged mouse cerebrum.

Authors:
Andrea D Rivera Francesca Pieropan Irene Chacon-De-La-Rocha Davide Lecca Maria P Abbracchio Kasum Azim Arthur M Butt

Aging Cell 2021 Mar 5:e13335. Epub 2021 Mar 5.

School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK.

Brain ageing is characterised by a decline in neuronal function and associated cognitive deficits. There is increasing evidence that myelin disruption is an important factor that contributes to the age-related loss of brain plasticity and repair responses. In the brain, myelin is produced by oligodendrocytes, which are generated throughout life by oligodendrocyte progenitor cells (OPCs). Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Agonist.

Authors:
Sekhar Surapaneni Usha Yerramilli April Bai Deepak Dalvie Jennifer Brooks Xiaomin Wang Julie V Selkirk Yingzhuo Grace Yan Peijin Zhang Richard Hargreaves Gondi Kumar Maria Palmisano Jonathan Q Tran

Drug Metab Dispos 2021 Mar 4. Epub 2021 Mar 4.

Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, United States of America.

Ozanimod is approved for the treatment of relapsing forms of multiple sclerosis. Absorption, metabolism and excretion of ozanimod was investigated following a single oral dose of 1.0 mg C-ozanimod hydrochloride to six healthy subjects. Read More

View Article and Full-Text PDF
March 2021
Similar Publications